Substitution of a conserved amino acid residue alters the ligand binding properties of peroxisome proliferator activated receptors

被引:8
作者
Causevic, M
Wolf, CR
Palmer, CNA [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Ninewells Hosp & Med Sch, Imperial Canc Res Fund, Mol Pharmacol Unit, Dundee DD1 9SY, Scotland
基金
英国生物技术与生命科学研究理事会;
关键词
nuclear receptor; peroxisome proliferator; fatty acid; fluorescence; thiazolidinedione; diabetes;
D O I
10.1016/S0014-5793(99)01618-X
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutation of glutamic acid 282 of PPAR alpha to glycine has been shown to result in an increased EC50 for a wide variety of PPAR activating compounds. This has suggested that mutant receptor has a reduced ability to bind ligand. In this study we show that this mutation reduces the affinity of mPPAR alpha and hPPAR gamma for the fluorescent fatty acid, cis-parinaric acid and that the mutant hPPAR gamma protein has:a reduced affinity for the radiolabelled compound, SB236636. These data confirm the role of this glutamic acid in ligand binding and support recent crystal structure observations regarding a proposed novel mode of ligand entry into the PPAR ligand binding cavities. (C) 1999 Federation of European Biochemical Societies.
引用
收藏
页码:205 / 210
页数:6
相关论文
共 30 条
[21]   The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation [J].
Ricote, M ;
Li, AC ;
Willson, TM ;
Kelly, CJ ;
Glass, CK .
NATURE, 1998, 391 (6662) :79-82
[22]   Thiazolidinediones in the treatment of insulin resistance and type II diabetes [J].
Saltiel, AR ;
Olefsky, JM .
DIABETES, 1996, 45 (12) :1661-1669
[23]   Differentiation and reversal of malignant changes in colon cancer through PPARγ [J].
Sarraf, P ;
Mueller, E ;
Jones, D ;
King, FJ ;
DeAngelo, DJ ;
Partridge, JB ;
Holden, SA ;
Chen, LB ;
Singer, S ;
Fletcher, C ;
Spiegelman, BM .
NATURE MEDICINE, 1998, 4 (09) :1046-1052
[24]   Loss-of-function mutations in PPARγ associated with human colon cancer [J].
Sarraf, P ;
Mueller, E ;
Smith, WM ;
Wright, HM ;
Kum, JB ;
Aaltonen, LA ;
de la Chapelle, A ;
Spiegelman, BM ;
Eng, C .
MOLECULAR CELL, 1999, 3 (06) :799-804
[25]  
SHA RS, 1993, J BIOL CHEM, V268, P7885
[26]   ADIPOCYTE-SPECIFIC TRANSCRIPTION FACTOR-ARF6 IS A HETERODIMERIC COMPLEX OF 2 NUCLEAR HORMONE RECEPTORS, PPAR-GAMMA AND RXR-ALPHA [J].
TONTONOZ, P ;
GRAVES, RA ;
BUDAVARI, AI ;
ERDJUMENTBROMAGE, H ;
LUI, M ;
HU, E ;
TEMPST, P ;
SPIEGELMAN, BM .
NUCLEIC ACIDS RESEARCH, 1994, 22 (25) :5628-5634
[27]   MPPAR-GAMMA-2 - TISSUE-SPECIFIC REGULATOR OF AN ADIPOCYTE ENHANCER [J].
TONTONOZ, P ;
HU, E ;
GRAVES, RA ;
BUDAVARI, AI ;
SPIEGELMAN, BM .
GENES & DEVELOPMENT, 1994, 8 (10) :1224-1234
[28]   STIMULATION OF ADIPOGENESIS IN FIBROBLASTS BY PPAR-GAMMA-2, A LIPID-ACTIVATED TRANSCRIPTION FACTOR [J].
TONTONOZ, P ;
HU, ED ;
SPIEGELMAN, BM .
CELL, 1994, 79 (07) :1147-1156
[29]   Molecular recognition of fatty acids by peroxisome proliferator-activated receptors [J].
Xu, HE ;
Lambert, MH ;
Montana, VG ;
Parks, DJ ;
Blanchard, SG ;
Brown, PJ ;
Sternbach, DD ;
Lehmann, JM ;
Wisely, GB ;
Willson, TM ;
Kliewer, SA ;
Milburn, MV .
MOLECULAR CELL, 1999, 3 (03) :397-403
[30]  
Young PW, 1998, J PHARMACOL EXP THER, V284, P751